Why the study?
Does bivalirudin reduce hemorrhagic complications compared to unfractionated heparin in pediatric patients on continuous flow ventricular assist device support?
Does bivalirudin reduce hemorrhagic complications compared to unfractionated heparin in pediatric patients on continuous flow ventricular assist device support?
In pediatric patients on CF-VAD support, bivalirudin is associated with fewer hemorrhagic complications compared to unfractionated heparin.
Answers are grounded in this paper and cite their sources.
May warrant consideration of bivalirudin in pediatric CF-VAD; leaves open need for RCTs to confirm benefit over UFH.
Use of bivalirudin for anticoagulation in patients on CF-VAD support was associated with lesser odds of hemorrhagic complications compared with use of UFH. Bivalirudin "washout" was successful in medical management of six of eight cases of possible pump thrombosis.
No takes yet. Share an insight, caveat, or question.
Puri et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: